Published in:
01-06-2014 | Original Article
Delayed 18F-fluorodeoxyglucose PET/CT imaging improves quantitation of atherosclerotic plaque inflammation: Results from the CAMONA study
Authors:
Björn A. Blomberg, MD, MSc, Anders Thomassen, MD, Richard A. P. Takx, MD, MSc, Malene G. Hildebrandt, MD, PhD, Jane A. Simonsen, MD, Karen M. Buch-Olsen, MD, Axel C. P. Diederichsen, MD, PhD, Hans Mickley, MD, DMSc, Abass Alavi, MD, PhD, DSc, Poul F. Høilund-Carlsen, MD, DMSc
Published in:
Journal of Nuclear Cardiology
|
Issue 3/2014
Login to get access
Abstract
Background
This study aimed to determine if delayed 18F-fluorodeoxyglucose (18FDG) PET/CT imaging improves quantitation of atherosclerotic plaque inflammation. Blood-pool activity can disturb the arterial 18FDG signal. With time, blood-pool activity declines. Therefore, delayed imaging can potentially improve quantitation of vascular inflammation.
Methods and Results
40 subjects were prospectively assessed by dual-time-point PET/CT imaging at approximately 90 and 180 minutes after 18FDG administration. For both time-points, global uptake of 18FDG was determined in the carotid arteries and thoracic aorta by calculating the blood-pool corrected maximum standardized uptake value (cSUVMAX). A target-to-background ratio (TBR) was calculated to determine the contrast resolution at 90 and 180 minutes. Furthermore, we assessed whether the acquisition time-point affected the relation between cSUVMAX and the estimated 10-year risk for fatal cardiovascular disease (SCORE %). A significant increase in carotid cSUVMAX (23%, P < .0001), carotid TBR (20%, P < .0001), aortic cSUVMAX (14%, P < .0001), and aortic TBR (20%, P < .0001) was observed with time. At 90 minutes, cSUVMAX did not relate to SCORE %, whereas at 180 minutes significant positive relations were observed between SCORE % and carotid (τ = 0.25, P = .045) and aortic (τ = 0.33, P = .008) cSUVMAX.
Conclusions
Delayed 18FDG PET/CT imaging at 180 minutes improves quantitation of atherosclerotic plaque inflammation over imaging at 90 minutes. Therefore, the optimal acquisition time-point to assess atherosclerotic plaque inflammation lies beyond the advocated time-point of 90 minutes after 18FDG administration.